In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.

Local drug delivery in recurrent malignant gliomas / A. Boiardi, M. Eoli, A. Salmaggi, E. Lamperti, A. Botturi, A. Solari, F. Di Meco, G. Broggi, A. Silvani. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 26:suppl. 1(2005), pp. S37-S39. ((Intervento presentato al convegno Lombardia Meeting of the Italian-Neurological-Society/Italian-Society-of-Hospital-Neurosciences tenutosi a Monza nel 2005.

Local drug delivery in recurrent malignant gliomas

A. Botturi;F. Di Meco;
2005

Abstract

In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.
glioblastoma; loco-regional chemotherapy; nimustine; doxorubicine
Settore MED/27 - Neurochirurgia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Boiardi2005_Article_LocalDrugDeliveryInRecurrentMa.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 37.17 kB
Formato Adobe PDF
37.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/588262
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 15
social impact